VP Global Market Access
San Diego California UNITED STATES
Ammar Qadan is currently and since Nov 2016 the Vice President and Global Market Access Lead at Illumina; a company whose mission is “to improve human health by unlocking the power of the genome”. In his current job, Ammar is responsible for Health Economics and Outcomes Research, Market Access/Pricing strategy, Field Market Access and Payer Policy and Advocacy. Ammar pioneered new approaches around market access to Next Generation Sequencing(NGS) including the development and execution of the first value-based contract in Next Generation Sequencing with Harvard Pilgrim. Through his career, Ammar has been distinguished as a passionate, innovative patient-focused Biotech leader who worked on multiple disease areas and biotechnology- related strategic programs and major corporate initiatives across functions and geographies. Before joining Illumina, Ammar was the Vice President and Global Product Team Lead at Halozyme Therapeutics, a Biotech focused on Oncology development in San Diego. He was instrumental in revamping their lead biomarker-driven oncology program strategy, leading to new clinical development programs and a major partnership with Roche/Genentech. Prior to joining Halozyme, Ammar spent nearly 20 years at Bristol Myers Squibb in roles of increasing complexity in areas like market access, marketing, country management and product development, where he worked & lived in 6 different countries across North America, Europe & the Middle East. Ammar’s experience includes therapeutic areas like Immuno-Oncology, Virology, Cardiovascular disease and Diabetes. Ammar is a Pharmacist by training and has been a panelist at BIO in 2014 and 2015